Abstract
Antibiotic Resistance Bacterial resistance to antibiotics is a growing worldwide problem, and Enterobacterales with resistance to the polymyxin class of antibiotics are a critical threat. De Oliveira et al. repurposed a hydroxyquinoline compound called PBT2, currently in phase 2 clinical trials for neurodegenerative diseases, to break polymyxin antibiotic resistance in four different Gram-negative pathogens, including Klebsiella pneumoniae and Pseudomonas aeruginosa . In vitro, treatment with PBT2 disrupted the abundance of zinc and iron in the resistant bacteria, whereas in immunocompetent septic mice, PBT2 combined with polymyxins resulted in improved survival with reduced bacterial dissemination. These findings, although exciting, need to be confirmed in humans. Sci. Transl. Med. 12 , eabb3791 (2020).
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
